HEALTH

NAD recommends modification to Aveeno ads

BY Michael Johnsen

NEW YORK The National Advertising Division of the Council of Better Business Bureaus last weeek recommended that Johnson & Johnson Consumer Companies modify or discontinue certain advertising claims made in print and Internet advertising and product packaging for its Aveeno Advanced Relief Cold Sore Tre atment.

The advertising claims were challenged by Wyeth Consumer HealthCare, makers of Chapstick Medicated Cold Sore Therapy and Anbesol Maximum Strength Pain Relief Cold Sore Therapy.

Wyeth asserted that the Aveeno product is being marketed as a cold sore/fever blister “advanced” treatment that has been “clinically proven effective” and “works to treat cold sores,” when, in fact, it contains only one active ingredient, a skin protectant that, “relieves dryness and softens crusts” associated with cold sores.

According to Wyeth’s challenge, Aveeno has no active ingredients that work to heal cold sores and is not “advanced” in any way beyond moisturizing.

Following its review of the advertising claims around Aveeno, NAD found that the evidence was insufficient to provide a reasonable basis for the advertiser’s “clinically proven effective” and “clinically proven way to treat cold sore symptoms up to 3 1/2 days faster” claims and recommended that they be discontinued.

NAD recommended also that the advertiser discontinue its use of phrases such as “Why spend even one more day with a cold sore?” as well as the side-by-side depiction of lips with cold sore and lips 3 1/2 days later, and any similar statements that convey an implied shortening of healing time or faster treatment message.

NAD did determine, however, that there was a reasonable basis existed for a more limited claim as to the fact that propolis may help to treat cold sore symptoms faster than placebo, and provides fast relief of cold sore symptoms.

Johnson & Johnson Consumer Companies, in its advertiser’s statement, stated the company is “very disappointed” and strongly disagrees with NAD’s decision “concerning the validity of the two clinical studies.”

However, the company noted, “we respect NAD’s self-regulatory process and will take NAD’s decision into account in any future advertising and will not be producing any additional inventory with the labeling at issue.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Adams files suit against Perrigo for Mucinex patent infringement

BY Michael Johnsen

CHESTER, N.J. Adams Respiratory Therapeutics on Thursday announced that it has filed a lawsuit in the United States District Court for the District of New Jersey against Perrigo for patent infringement of its Mucinex line of oral solid, extended-release guaifenesin products. Adams claims that the patents protecting Mucinex don’t expire until 2020.

Adams filed the lawsuit in response to Perrigo’s notification that it filed a Paragraph IV Certification in connection with its Abbreviated New Drug Application, which seeks Food and Drug Administration approval to engage in the commercial manufacture, use or sale of guaifenesin 600 mg single-ingredient, extended-release tablets (equivalent to Adams’ Mucinex SE), prior to the expiration of the patent. This patent infringement lawsuit will automatically stay the FDA from approving Perrigo’s ANDA until the earlier of 30 months or until a district court rules in favor of Perrigo.

Adams markets six patent-protected extended-release guaifenesin products over-the-counter under the Mucinex brand name, including a new line of 1,200 mg maximum-strength products. These products are the only available FDA-approved extended-release guaifenesin products, the company claimed. Perrigo’s ANDA relates only to guaifenesin 600 mg single-ingredient, extended-release tablets.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Survey results show baby boomers’ pains affect their active lifestyles

BY Michael Johnsen

FORT WASHINGTON, Pa. Results from a new national “Pain Poll” survey issued Friday of 50-something baby boomers found that while 77 percent of boomers think “50 is the new 40,” unfortunately 55 percent of baby boomers said that their aches and pains have affected their ability to maintain an active lifestyle.

The good news for 50-somethings is that 72 percent of males and females surveyed by the Pain Poll feel mentally 10 years younger than the age on their driver’s license; in contrast, the poll showed that 62 percent of 50-somethings feel physically the same as or older than the age on their driver’s license.

Overall, the Pain Poll found that 92 percent of 50-somethings have experienced aches and pains, and 52 percent said they experience aches and pains on a daily basis.

“Remaining active and exercising for 50-somethings may be harder because of increased joint and early osteoarthritis pain, but at this age it is important to keep exercising because this will strengthen muscles and help to reduce stress on the joints that they support,” stated Dr. Rosa Solorio.

Solorio is working with McNeil Consumer Healthcare, with support from the Arthritis Foundation, to help educate 50-something baby boomers about the importance of exercising and maintaining a healthy lifestyle. The education initiative includes the Keep Moving program, which was initiated by McNeil.

The Pain Poll was sponsored by McNeil Consumer Healthcare, the makers of Tylenol, and conducted by Harris Interactive.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?